HQP1351

DRUG5 trials

Conditions

Chronic Myeloid Leukemia - Accelerated PhaseChronic Myeloid Leukemia, Chronic PhaseGastrointestinal Stromal Tumor (GIST)Solid Tumor, Adult

Phase 1

A Study of HQP1351 in Patients With GIST or Other Solid Tumors

RecruitingNCT03594422

Ascentage Pharma Group Inc.Gastrointestinal Stromal Tumor (GIST), Solid Tumor, Adult

Start: 2018-07-11End: 2026-12-31Target: 100Updated: 2025-02-27

Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia

CompletedNCT03882281

Ascentage Pharma Group Inc.Chronic Myeloid Leukemia, Chronic Phase

Start: 2019-03-25End: 2019-11-16Updated: 2020-01-22

Phase 2

A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation

NCT03883087

Ascentage Pharma Group Inc.Chronic Myeloid Leukemia, Chronic Phase

Start: 2019-04-08End: 2025-02-28Updated: 2023-04-03

A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation

NCT03883100

Ascentage Pharma Group Inc.Chronic Myeloid Leukemia - Accelerated Phase

Start: 2019-04-08End: 2025-03-31Updated: 2023-04-03

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

CompletedNCT04126681

Ascentage Pharma Group Inc.Chronic Myeloid Leukemia, Chronic Phase

Start: 2019-10-21End: 2024-08-01Updated: 2025-03-03

2025-11-041 citations

Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-Phase chronic myeloid leukemia (CML-CP) in a registrational randomized Phase 2 trial: Up to 4-year follow-up including patients without T315I mutations

Blood2025-11-03

Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma.

Journal of Clinical Oncology2024-06-0111 citations

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Blood2023-11-0210 citations

Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)–resistant succinate dehydrogenase (SDH)–deficient gastrointestinal stromal tumor (GIST).

Journal of Clinical Oncology2023-06-013 citations

Olverembatinib Demonstrates Promising Results in T315I-Mutant CML

Oncology Times2023-02-201 citations

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

Blood2022-11-1510 citations

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Journal of Hematology & Oncology2022-08-1889 citations

Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST).

Journal of Clinical Oncology2022-06-014 citations

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant <i>BCR-ABL1 T315I</i>-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)

Blood2021-11-0511 citations

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Blood2020-11-0525 citations

HQP1351

Sponsors

Conditions

Phase 1

Phase 2

Related Papers